https://medicine.ouhsc.edu/Directory Parent Page: Directory id: 22535 Active Page: Detailsid:23325

Directory

Categories

Kar-Ming Fung, MD, PhD
Pathology

Kar-Ming Fung, MD, PhD

Professor Neuropathology/Surgical Pathology
Adjunct Professor Urology
Director of Neuropathology
Director of Electron Microscopy


OU Medical Center
Presbyterian Tower
Lower Level, Pathology Suite
700 N.E. 13th St.
Oklahoma City, OK 73104

405-271-8001, x37711

karming-fung@ouhsc.edu


Academic Section(s):

Pathology


Education:

  • Taipei Medical College
    Taipei, Taiwan
    MD (1988)
  • University of Pennsylvania
    Philadelphia, Pennsylvania
    PhD, Pathology (1994)
  • Diplomate - American Board of Pathology
    Anatomic Pathology and Neuropathology


Fellowship:

  • Mackay Memorial Hospital
    Residency - Anatomic Pathology
  • New York University
    Residency - Anatomic Pathology
  • University of Pennsylvania
    Philadelphia, Pennsylvania
    Fellow - Neuropathology
  • University of Texas
    M.D. Anderson Cancer Center
    Fellow - Surgical Pathology


Clinical/Research Interests:

The biology of brain tumor with special emphasis on the cell proliferation and cell death of medulloblastoma cells and their response to chemotherapeutic drugs.


Select Honors & Accomplishments:

  • American Association of Neuropathologists (AANP), member of the Professional Affairs Committee. 2007.
  • Regents Award for Superior Teaching. 2008.


Select Publications:

List of Publications on PubMed

  1. Conner AK, Fung KM, Peterson JE, Glenn CA, Martin MD. Ectopic ganglion in cauda equina: case report. J Neurosurg Spine. 2016 Feb 12:1-4. [Epub ahead of print] PMID: 26871650

  2. Tran HH, McNall-Knapp RY, Gross NL, Alleman AM, Yu Z, Orr BA, Fung KM. Medulloepitheliomatous component of immature teratoma lacks amplification at chromosome 19q13.42 locus – report of a case. Int J Clin Exp Pathol. 2016;9(1):345-352. Epub 2016 January 1. Published 2016 January 15.
  3. Franco-Palacios MA, Martin MD, Wierenga K, Lake JR, Davis AC, Wartchow EP, Mierau GW, Fung KM. Adult polyglucosan body disease with reduced glycogen branching enzyme activity and heterozygous GBE1 mutation mimicking a low-grade glioma [Case Report]. Int J Clin Exp Pathol. 2016;9(3):4092-4100. Epub 2016 March 1. Published 2016 March 15.
  4. Ziegler J, Pody R, Coutinho de Souza P, Evans B, Saunders D, Smith N, Mallory S, Njoku C, Dong Y, Chen H, Dong J, Lerner M, Mian O, Tummala S, Battiste J, Fung KM, Wren JD, Towner RA. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models. Neuro Oncol. 2016 Jul 14. doi: 10.1093/neuonc/now147 [Epub ahead of print] PMID: 27416955 .
  5. Yang J, Hannafon BN, Zhang RR, Fung KM, Ding WQ. Docosahexaenoic acid and disulfiram act in concert to kill cancer cells: a mutual enhancement of their anticancer actions. Oncotarget. 2017 Jan 17. doi: 10.18632/oncotarget.14702. [Epub ahead of print] PMID: 28107189

  6. Wang HC, Qian L, Zhao Y, Mengarelli J, Adrianto I, Montgomery CG, Urban JF Jr, Fung KM, Sun XH. Downregulation of E protein activity augments an ILC2 differentiation program in the thymus. J Immunol. 2017 Mar 3. pii: 1602009. doi: 10.4049/jimmunol.1602009. [Epub ahead of print] PMID: 28258196

  7. Vuong HG, Altibi AMA, Duong UNP, Ngo HTT, Pham TQ, Fung KM, Hassell L. BRAF mutation is associated with an improved survival in glioma-a systematic review and meta-analysis. Mol Neurobiol. 2017 May 22. doi: 10.1007/s12035-017-0599-y. [Epub ahead of print] PMID: 28534272

  8. Borre PV, Schrock AB, Anderson PM, Morris III JC, Heilmann AM, Holmes O, Wang K, Johnson A, Waguespack SG, Ou SI, Khan S, Fung KM, Stephens JP, Erlich RL, Miller VA, Ross JS, Ali SM. Pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including kinase fusions. Oncologist 2017 Mar;22(3):255-263. doi: 10.1634/theoncologist.2016-0279. Epub 2017 Feb 16. PMID: 28209747

  9. Krais JJ, Virani N, McKenan PH, Nguyen Q, Fung KM, Sikavitsas VI, Kurkjian CD, Harrison RG. Antitumor synergism and enhanced survival with a tumor vasculature-targeted enzyme prodrug system, rapamycin, and cyclophosphamide. Mol Cancer Ther. 2017 May 18. pii: molcanther.0263.2016. doi: 10.1158/1535-7163.MCT-16-0263. [Epub ahead of print] PMID: 28522586

Web Pages